Analysts See $1.31 EPS for Novartis AG (NVS)

June 14, 2018 - By Marry Poplack

Novartis AG (NYSE:NVS) Logo

Analysts expect Novartis AG (NYSE:NVS) to report $1.31 EPS on July, 17.They anticipate $0.10 EPS change or 8.26 % from last quarter’s $1.21 EPS. NVS’s profit would be $3.34B giving it 14.50 P/E if the $1.31 EPS is correct. After having $1.28 EPS previously, Novartis AG’s analysts see 2.34 % EPS growth. The stock increased 0.25% or $0.19 during the last trading session, reaching $75.98. About 1.30M shares traded. Novartis AG (NYSE:NVS) has declined 6.45% since June 14, 2017 and is downtrending. It has underperformed by 19.02% the S&P500.

Novartis AG (NYSE:NVS) Ratings Coverage

Among 4 analysts covering Novartis (NYSE:NVS), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Novartis had 4 analyst reports since January 25, 2018 according to SRatingsIntel. The rating was maintained by Leerink Swann on Thursday, January 25 with “Market Perform”. The firm has “Hold” rating given on Tuesday, May 29 by HSBC. The company was maintained on Friday, February 2 by Cowen & Co. The stock of Novartis AG (NYSE:NVS) earned “Neutral” rating by Credit Suisse on Friday, May 25.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company has market cap of $193.56 billion. The companyÂ’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It has a 23.38 P/E ratio. This divisions also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies.

More notable recent Novartis AG (NYSE:NVS) news were published by: Seekingalpha.com which released: “Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases” on June 12, 2018, also Seekingalpha.com with their article: “Novartis: Exit Sandoz US Now” published on June 06, 2018, Prnewswire.com published: “Over Half of Patients with Vision Issues do not Seek Help After Visiting a Doctor for Concussion” on June 13, 2018. More interesting news about Novartis AG (NYSE:NVS) were released by: Seekingalpha.com and their article: “Veeva Systems: Expanding Its Growth Runway Ahead” published on June 08, 2018 as well as Seekingalpha.com‘s news article titled: “Novartis lawyer out amid Cohen payments” with publication date: May 16, 2018.

Novartis AG (NYSE:NVS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: